Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Syns- og hørselsundersøkelse av effekter på delirium (SHIELD)

27. oktober 2026 oppdatert av: Johns Hopkins University

Prospektivt initiativ for å undersøke og behandle hørselstap, synstap og delirium i sykehusmiljø

The goal of this observational study is to learn about sensory loss in hospital patients with delirium. The main questions it aims to answer are:

  • Are hearing and vision loss related to increased risk of having delirium?
  • Do hearing and vision loss contribute to more severe delirium?
  • Do sensory loss and/or delirium affect patient satisfaction with hospital care?

Participants will be asked to:

  • answer delirium screening questions,
  • undergo hearing & vision screenings, and
  • complete questionnaires about the hospital stay.

The second part of this study is a clinical trial. Researchers will compare different hospital units to see if changing communication affects the number of patients with delirium. The main questions it aims to answer are:

• Does sharing information about communication and/or providing hearing devices change the number of hospital patients with delirium?

Participants in the study will be asked to complete delirium screenings and answer questions about their hearing and communication.

Studieoversikt

Detaljert beskrivelse

This is a prospective cohort study entitled Sight & Hearing Investigation into Effects on Delirium (SHIELD), which aims of to characterize the impact of sensory impairment (i.e., vision and/or hearing loss) on inpatient delirium and experience. The initial phase of this research includes delirium, hearing, and vision screenings, as well as questionnaires regarding satisfaction with care, all of which are observational and do not constitute treatment or intervention. Researchers will conduct electronic medical record reviews to determine whether new patients have been admitted to the units of recruitment on a daily basis and collect relevant demographic and medical information. Eligible patients will be screened to with the 4AT identify delirium and the 3D-CAM-S to characterize delirium severity. After obtaining informed consent, patients will undergo bedside hearing and vision screenings, and complete patient satisfaction questionnaires.

Studietype

Observasjonsmessig

Registrering (Faktiske)

1312

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Maryland
      • Baltimore, Maryland, Forente stater, 21224
        • Johns Hopkins Bayview Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

65 år og eldre (Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Participants over the age of 60 who was admitted to Bayview Medicine A, B, or C who meet inclusion criteria.

Beskrivelse

Inclusion Criteria:

  • inpatient on Johns Hopkins Bayview Medicine A, Medicine B, or Carol Ball unit
  • communicates using speech and language
  • able to converse in English

Exclusion Criteria:

  • nonverbal
  • unable to communicate using English language
  • currently under airborne or droplet isolation precautions

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: ECOLOGIC_OR_COMMUNITY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Delirium & Sensory Loss

The observational portion of the study, during which participants are screened for delirium. Consented individuals also complete bedside hearing and vision screenings, and provide information regarding care on patient satisfaction questionnaires.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Delirium as Assessed by 4AT Rapid Clinical Test for Delirium (4AT)
Tidsramme: Approximately daily during hospitalization up to 6 months

Diagnosis of delirium using 4AT Rapid Clinical Test for Delirium (4AT). This test has a score range of 0 to 12, with a score of 4 or more indicating a positive delirium result. A score between 1 and 3 is indicative of possible cognitive impairment. Delirium symptom severity can be informally inferred from the test score, but the study will not be using the 4AT Rapid Clinical Test for Delirium (4AT) to measure delirium severity.

Approximately daily during hospitalization up to 6 months
Percentage of Participants With Delirium as Assessed by 4AT Rapid Clinical Test for Delirium in Proportion to Total Number of Patients Screened
Tidsramme: Approximately daily during hospitalization up to 6 months

Counts of delirium diagnosed using 4AT Rapid Clinical Test for Delirium (4AT) score of 4 or greater, in comparison to the total number of patients screened.

The 4AT Rapid Clinical Test for Delirium (4AT) has a score range of 0 to 12, with a score of 4 or more indicating a positive delirium result. A score between 1 and 3 is indicative of possible cognitive impairment. Delirium symptom severity can be informally inferred from the test score, but the study will not be using the 4AT Rapid Clinical Test for Delirium (4AT) to measure delirium severity.

Approximately daily during hospitalization up to 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Severity of Delirium Quantified by the 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium (3D-CAM)
Tidsramme: Approximately daily during hospitalization up to 6 months

Study participants who score a 1 or higher on the 4AT Rapid Clinical Test for Delirium (4AT) over the duration of time inpatient on the three hospital units of recruitment (Johns Hopkins Bayview Medicine A, Medicine B, and Carol Ball units). Quantification of delirium severity from 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium Severity (3D-CAM-S) score. The possible range of scores is from 0 to 20, with a higher number indicating the presence of more delirium signs and symptoms. However, the diagnosis of delirium using this metric depends on the presence of four characteristic features of delirium. Scores summed and averaged over the data collection period.

Approximately daily during hospitalization up to 6 months
Satisfaction With Care Assessed Using the Questionnaire on the Quality of Physician-Patient Interaction (QQPI)
Tidsramme: Once during hospitalization up to 6 months

Self-reported satisfaction with hospital care from scores on Questionnaire on the Quality of Physician-Patient Interaction (QQPPI) and/or Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) measures.

Possible scores on the QQPPI range from 14 to 70; higher scores indicate higher patient satisfaction.

Once during hospitalization up to 6 months
Satisfaction With Care Assessed Using the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
Tidsramme: Once during hospitalization up to 6 months

Self-reported satisfaction with hospital care from scores on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) measures. Possible scores on the HCAHPS range from 11 to 62 regarding the hospital stay; between 0-4 on each of the two personal health questions; 0-10 for overall hospital rating. Higher scores are better.

Once during hospitalization up to 6 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hearing Sensitivity as Quantified With Four-Frequency Pure Tone Average (PTA) for the Better-Hearing Ear
Tidsramme: Once during hospitalization up to 6 months

Hearing sensitivity will be quantified based on the average of thresholds measured for four pure tone frequencies (500, 1000, 2000, and 4000 Hz). Thresholds will be measured under earphones during an iPad-based SHOEBOX audiometric screening. PTA values range from -20 to 90 decibels hearing level (dB HL). A higher pure tone average (PTA) suggests that higher signal intensities were necessary for the participant to hear and respond to the stimuli, which also suggests poorer hearing.

World Health Organization categories for PTA are include 25 or less: no impairment, 26 to 40: slight impairment, 41 to 60: moderate impairment, 61 to 80: severe impairment, and 81 or greater: profound impairment including deafness.

Once during hospitalization up to 6 months
Binocular Distance Visual Acuity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Tidsramme: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Distance visual acuity will be measured at 5 feet. Scores range from 50/20 to 4/20, with smaller numbers indicating better distance visual acuity.

Once during hospitalization up to 6 months
Binocular Contrast Sensitivity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Tidsramme: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Contrast sensitivity will also be measured at a distance of 5 feet. Scores for this test range from 0.5 to 2.0 with a larger score indicating better contrast sensitivity.

Once during hospitalization up to 6 months
Binocular Near Visual Acuity Quantified With E-Book From National Health and Aging Trends Study (NHATS)
Tidsramme: Once during hospitalization up to 6 months

Vision screenings will be performed using the National Health and Aging Trends Study (NHATS) Vision e-book developed by Ridgevue Vision on an iPad. Participants will not use glasses or contacts during the testing.

Near visual acuity will be measured at usual reading distance. Scores for this test range from 32/20 to 2.5/20, with smaller numbers indicating better near visual acuity.

Once during hospitalization up to 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nicholas S Reed, Au.D., Ph.D., Assistant Professor, Department of Epidemiology
  • Hovedetterforsker: Esther Oh, MD, Ph.D., Associate Professor, Departments of Medicine and Psychiatry

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. januar 2023

Primær fullføring (Faktiske)

15. desember 2023

Studiet fullført (Faktiske)

15. desember 2023

Datoer for studieregistrering

Først innsendt

7. desember 2023

Først innsendt som oppfylte QC-kriteriene

7. desember 2023

Først lagt ut (Faktiske)

20. desember 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Limited data sets of information may be available to other researchers, pending approval of the Johns Hopkins Medicine Institutional Review Board.

For participants who have provided informed consent, this information includes demographics (age, sex, race), Charlson comorbidity index score, delirium screening and severity results, hearing screening results, vision screening results, and patient satisfaction data.

For patients who qualified for study inclusion under waivers of documentation of informed consent and HIPAA, this information includes demographics (age, sex, race) and delirium screening and severity results.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere